Protara Therapeutics is trading at $3.50, down 5.03%, as weaker major U.S. indexes, rising oil prices and Treasury yields pressure risk appetite and equity valuations. - No company-specific catalyst was identified on September 23, 2026; the company’s official investor-relations page shows no announcement that day. - Biotech is outperforming broader markets, so the move appears more macro-driven than sector-specific. - Confidence is medium.